Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies in Clinical Pipeline
Delhi, India (PRWEB) August 09, 2014
Recent years have witnessed the emergence of cancer immunotherapy, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past 15 years, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. Cancer immunotherapy has been made commercial and the market availability of the agents has enabled the pharma companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system.
Recently published research study “Cancer Immunotherapy Market & Clinical Pipeline Insight” by KuicK Research study highlights the ongoing developments and trends in the field of cancer immunotherapy. Research study gives comprehensive insight on clinical information like patent analysis, orphan designation, companies developing immunotherapy drugs, on more than 1000 cancer immunotherapy being developed for the treatment of multiple cancers. Report discusses various Antibodies, Cancer Vaccine, Cell Therapies, Oncolytic viruses and cytokines therapies being clinical developed for the treatment of multiple cancers.
“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:
- Cancer Immunotherapy Market Overview
- Cancer Immunotherapy Market Dynamics
- Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
- Marketed Cancer Immunotherapy Therapy: 64 Marketed
- Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
- Cancer Vaccine Clinical Pipeline by Phase & Country
- Oncolytic Viruses Clinical Pipeline by Phase & Country
- Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
- Cancer Cell Therapy Clinical Trial Insight by Phase & Country
- Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies in Clinical Pipeline
“Cancer Immunotherapy Market & Clinical Pipeline Insight” report gives insight on the following cancer immunotherapies:
- Cancer Monoclonal Antibodies: 34 Marketed & 605 In Clinical Development Phases
- Cancer Vaccines: 12 Marketed & 289 In Clinical Development Phases
- Cancer Cell Therapy: 3 Marketed & 82 In Clinical Development Phases
- Cancer Cytokine Therapy: 15 Marketed & 64 In Clinical Development Phases
- Oncolytic Virus Therapy: 40 In Clinical Development Phases
“Cancer Immunotherapy Market & Clinical Pipeline Insight” report highlights US dominance in the clinical development of cancer immunotherapies followed by European region. Reports discussed the mechanism of immunotherapies, types of immunotherapies, need for cancer immunotherapy, cancer immunotherapy market overview and clinical developments in fields of cancer immunotherapy.
For report sample contact:
Mr. Neeraj Chawla
+91-11-47067990
neeraj(at)kuickresearch(dot)com
